• OPG-001: An investigational gene therapy for Leber Congenital Amaurosis type 5 (LCA5), an inherited retinal disease.
• OPG-002: An investigational gene therapy for Leber Congenital Amaurosis type 13 (LCA13), another form of inherited retinal disease.
• OPG-003: An investigational gene therapy aimed at treating Best disease, a different inherited retinal degenerative condition.

There appears to be a factual inaccuracy in the company details provided. Opus Genetics was a private biotechnology company focused on developing gene therapies for inherited retinal diseases. It was not a public company and therefore did not trade under the stock symbol IRD. The symbol IRD belongs to a different public company, IRadimed Corporation.

Opus Genetics was acquired by Astellas Pharma (TYO: 4503) through its subsidiary XyloCor Therapeutics in 2023. Prior to its acquisition and as a clinical-stage biotech company, Opus Genetics did not have traditional "major customers" in the sense of selling commercial products to individuals or other companies. Its business model revolved around research, development, and clinical trials of its therapeutic candidates.

Considering its operational model, its primary "customers" or key partners could be identified as entities involved in its development pipeline:

• Pharmaceutical/Biotechnology Companies: As a pre-commercial biotech company, its ultimate "customer" in a strategic sense was its acquirer. Opus Genetics was acquired by Astellas Pharma (TYO: 4503), which took over its assets and pipeline. Other larger pharmaceutical or biotech companies would have been potential licensing partners for its technology and pipeline.
• Clinical Research Organizations (CROs) and Academic Medical Centers: These institutions served as partners for conducting clinical trials for Opus Genetics' investigational therapies. While technically service providers to Opus, they were integral to its scientific development process as collaborators in advancing its drug candidates.

Therefore, Opus Genetics primarily operated in a business-to-business (B2B) model through strategic partnerships, collaborative research, and eventual acquisition, rather than direct sales of commercial products to individuals or retail companies.

null

George Magrath, MD, MBA, MS Chief Executive Officer

Dr. George Magrath serves as the Chief Executive Officer and a Board member of Opus Genetics. He previously held the CEO position at Ocuphire Pharma, Inc. when it acquired Opus Genetics, and subsequently Ocuphire Pharma, Inc. became Opus Genetics, Inc. (NASDAQ: IRD). Before his tenure at Ocuphire Pharma, Dr. Magrath was the CEO of Lexitas Pharma Services, a prominent contract research organization specializing in ophthalmology.

Robert Gagnon, CPA, MBA Chief Financial Officer

Robert Gagnon serves as the Chief Financial Officer of Opus Genetics. Prior to joining Opus Genetics, Mr. Gagnon was the Chief Financial Officer and Treasurer of Galera Therapeutics, Inc., a publicly traded biotechnology company, where he oversaw finance, accounting, investor relations, and facilities functions. His career also includes serving as CFO at several private biotechnology companies, including OpGen, Inc. and Vanda Pharmaceuticals Inc., where he played a key role in their IPOs and subsequent financing activities. He was also instrumental in the acquisition of OpGen by Curetis N.V.. Mr. Gagnon's experience includes over 25 years in financial management within the life sciences sector, with leadership roles at companies like MedImmune, LLC (now AstraZeneca), and Macrogenics. He began his career at Ernst & Young.

Ben Yerxa, PhD President

Dr. Ben Yerxa is the President of Opus Genetics, having previously served as its Chief Executive Officer and President from September 2021. He was a driving force behind the launch of Opus Genetics. Dr. Yerxa previously held the role of Chief Executive Officer of the Foundation Fighting Blindness (FFB) starting in October 2017, where he established the Retinal Degeneration Fund (RD Fund), a venture philanthropy investment fund. Opus Genetics is the first spin-off company conceived and launched by the RD Fund, demonstrating his pattern of managing companies backed by private equity-like ventures. Before his time at FFB, Dr. Yerxa co-founded and served as President of Envisia Therapeutics, Inc., a company dedicated to developing ocular sustained delivery therapies. He also held founding and executive positions at various ophthalmology-focused research organizations, including Liquidia Technologies, Inc., Clearside Biomedical, Inc., Parion Sciences, Inc., and Inspire Pharmaceuticals, Inc.. Dr. Yerxa holds 60 U.S. patents.

Joe Schachle Chief Operating Officer

Joe Schachle serves as the Chief Operating Officer of Opus Genetics, joining the company as part of its founding executive team. He contributes deep operational experience, specifically in strategic planning, business development, and operations, which is crucial for building the company and establishing efficient orphan manufacturing at scale.

Ash Jayagopal, PhD, MBA Chief Scientific and Development Officer

Dr. Ash Jayagopal is the Chief Scientific and Development Officer at Opus Genetics. He joined Opus Genetics with over 13 years of experience in drug development, drug delivery platforms, and biomarker development for retinal diseases. Prior to Opus Genetics, Dr. Jayagopal was the executive director of discovery medicine at Kodiak Sciences, where he led the drug discovery team and strategized leveraging biopolymer technology for drug delivery in retinal diseases. He also served as the head of molecular pharmacology and biomarkers in ophthalmology at Roche, where he built and led a team of over 25 scientists focused on discovering and validating biologics, small molecules, and gene therapies for ocular diseases, including inherited retinal diseases.

The rapid advancement and clinical application of gene editing technologies, such as CRISPR and prime editing, represent a clear emerging threat to Opus Genetics.

While Opus Genetics focuses on adeno-associated virus (AAV)-based gene replacement therapies for inherited retinal diseases, gene editing platforms being developed by companies like Editas Medicine and Prime Medicine offer the potential for more precise, durable, and comprehensive genetic correction. The demonstrated viability and clinical progress of *in vivo* gene editing in ocular diseases by these and other companies suggest a potential paradigm shift that could diminish the long-term competitiveness of AAV gene replacement approaches.

Opus Genetics (symbol: IRD) focuses on developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The addressable markets for their main products and services are as follows:

• OPGx-LCA5 (for LCA5-associated inherited retinal disease): Approximately 1,000 patients in the U.S.
• OPGx-BEST1 (for BEST1-related inherited retinal disease/bestrophinopathy): Approximately 9,000 patients in the U.S.
• Retinitis Pigmentosa (a category that includes programs like OPGx-RHO): Approximately 5,600 patients in the U.S.
• OPGx-RDH12 (for RDH12-related Leber congenital amaurosis): Approximately 1,100 patients in the U.S.
• Phentolamine Ophthalmic Solution 0.75% (for presbyopia): More than 128 million people in the U.S.. The global presbyopia market is valued at over $2 billion.

Opus Genetics (NASDAQ: IRD) is a clinical-stage ophthalmic biopharmaceutical company primarily focused on developing therapies for inherited retinal diseases (IRDs) and other ophthalmic disorders. The company's future revenue growth over the next 2-3 years is expected to be driven by the advancement and potential commercialization of its pipeline assets:

1. Advancement and Potential Commercialization of Lead Gene Therapy Programs (OPGx-LCA5 and OPGx-BEST1): Opus Genetics is developing adeno-associated virus (AAV)-based gene therapies for IRDs. OPGx-LCA5, a Phase 1/2 candidate for Leber congenital amaurosis (LCA5), has shown encouraging early data, with plans to enroll pediatric patients in the first quarter of 2025. OPGx-BEST1, targeting BEST1-related retinal degeneration, is slated to begin a Phase 1/2 study in 2025. Positive clinical trial results and subsequent regulatory approvals for these lead programs are critical for future revenue generation, with recent financing specifically aimed at advancing them.

2. Commercialization of Phentolamine Ophthalmic Solution 0.75% for Presbyopia and Reduced Low Light Vision: The company is advancing Phentolamine Ophthalmic Solution 0.75%, which is currently in Phase 3 trials for presbyopia and reduced dim (mesopic) light vision/nighttime visual disturbances. This partnered therapy, already approved for one indication, represents an opportunity for revenue growth upon successful completion of trials and subsequent market launch for these new indications.

3. Advancement of APX3330 for Diabetic Retinopathy: Opus Genetics is developing APX3330, a small-molecule inhibitor of Ref-1, aimed at slowing the progression of non-proliferative diabetic retinopathy (DR). The company has reached an agreement with the FDA on a Special Protocol Assessment (SPA) for a Phase 3 trial for oral APX3330, indicating a clear pathway for its clinical development and potential entry into a significant market.

4. Expansion and Progression of its Broader Gene Therapy Pipeline: Beyond its lead candidates, Opus Genetics is also developing gene therapies for other IRDs caused by mutations in genes such as RHO, RDH12, MERTK, NMNAT-1, and CNGB1. Although these are earlier-stage programs, successful progression through preclinical and clinical development could diversify the company's product portfolio and contribute to long-term revenue growth, potentially seeing initial clinical milestones within the 2-3 year timeframe.

Share Issuance

• In March 2025, Opus Genetics conducted a public offering that raised $20 million through the sale of 21.05 million shares of common stock and warrants, alongside a concurrent private placement generating $1.5 million from 1.18 million shares and warrants.
• The warrants issued in March 2025 could yield an additional $21.4 million upon exercise, potentially bringing the total gross proceeds from these offerings to approximately $43 million.
• In November 2025, the company announced a registered direct offering with anticipated gross proceeds of approximately $23 million through the sale of common shares and pre-funded warrants.

Inbound Investments

• Opus Genetics, an inherited retinal disease gene therapy company launched in 2021 by the Foundation's RD Fund, merged with Ocuphire in October 2024, resulting in the combined entity trading under the symbol "IRD" on NASDAQ.
• The March 2025 public offering was led by Perceptive Advisors and Nantahala Capital, attracting participation from other new institutional biotech investors.
• Perceptive Advisors, Balyasny Asset Management, and Nantahala Capital led the November 2025 registered direct offering, indicating continued institutional investment.

Capital Expenditures

• Net proceeds from the March 2025 and November 2025 offerings are primarily allocated to fund the clinical development of lead gene therapy programs, specifically OPGx-LCA5 and OPGx-BEST1.
• Significant capital is being directed towards advancing OPGx-LCA5, currently in a Phase 1/2 clinical trial with plans to enroll pediatric patients in the first quarter of 2025.
• Expenditures also support the initiation of a Phase 1/2 clinical trial for OPGx-BEST1 in Germany in 2025, along with the progression of Phentolamine Ophthalmic Solution 0.75% and APX3330 through Phase 3 trials.